Dendreon to restructure after drop in cancer drug sales
November 12, 2013 at 09:13 AM EST
Nov 12 (Reuters) - Biotechnology company Dendreon Corp said it would restructure to cut costs after reporting another quarter of weak sales of its prostate cancer vaccine, Provenge.
